HC Wainwright Issues Pessimistic Forecast for SLDB Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – Research analysts at HC Wainwright cut their FY2025 earnings per share estimates for Solid Biosciences in a research note issued on Wednesday, November 5th. HC Wainwright analyst A. He now anticipates that the company will post earnings per share of ($1.98) for the year, down from their previous estimate of ($1.87). The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Solid Biosciences’ Q4 2025 earnings at ($0.51) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.52) EPS, Q3 2026 earnings at ($0.53) EPS, FY2026 earnings at ($2.12) EPS and FY2027 earnings at ($1.76) EPS.

Several other analysts have also issued reports on SLDB. Citigroup dropped their target price on shares of Solid Biosciences from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Solid Biosciences in a research note on Wednesday, October 8th. Wedbush dropped their price target on Solid Biosciences from $17.00 to $14.00 and set an “outperform” rating for the company in a research report on Wednesday, August 13th. Cantor Fitzgerald set a $16.00 price objective on Solid Biosciences and gave the company an “overweight” rating in a research note on Monday, July 21st. Finally, JPMorgan Chase & Co. decreased their price objective on Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating on the stock in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Solid Biosciences has an average rating of “Moderate Buy” and a consensus target price of $14.70.

Solid Biosciences Stock Performance

Shares of NASDAQ SLDB opened at $4.22 on Friday. The firm has a fifty day moving average of $5.59 and a 200 day moving average of $5.04. The firm has a market cap of $328.78 million, a PE ratio of -1.69 and a beta of 2.75. Solid Biosciences has a one year low of $2.41 and a one year high of $7.37.

Solid Biosciences (NASDAQ:SLDB) last announced its earnings results on Monday, November 3rd. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.06).

Hedge Funds Weigh In On Solid Biosciences

Institutional investors have recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. boosted its holdings in Solid Biosciences by 285.0% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 6,729,484 shares of the company’s stock valued at $24,899,000 after purchasing an additional 4,981,400 shares during the last quarter. Bain Capital Life Sciences Investors LLC grew its position in Solid Biosciences by 96.1% in the first quarter. Bain Capital Life Sciences Investors LLC now owns 7,911,669 shares of the company’s stock worth $29,273,000 after acquiring an additional 3,877,087 shares during the period. Siren L.L.C. grew its position in Solid Biosciences by 97.8% in the first quarter. Siren L.L.C. now owns 7,415,905 shares of the company’s stock worth $27,439,000 after acquiring an additional 3,666,864 shares during the period. MPM Bioimpact LLC acquired a new stake in Solid Biosciences during the first quarter worth $6,077,000. Finally, Nantahala Capital Management LLC raised its position in Solid Biosciences by 505.4% in the second quarter. Nantahala Capital Management LLC now owns 1,703,336 shares of the company’s stock valued at $8,295,000 after purchasing an additional 1,421,968 shares during the period. 81.46% of the stock is owned by hedge funds and other institutional investors.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.